Display Settings:

Format

Send to:

Choose Destination
Front Immunol. 2012 May 29;3:128. doi: 10.3389/fimmu.2012.00128. eCollection 2012.

Protective immunity and vaccination against cutaneous leishmaniasis.

Author information

  • 1Department of Medical Microbiology, University of Manitoba Winnipeg, MB, Canada.

Abstract

Although a great deal of knowledge has been gained from studies on the immunobiology of leishmaniasis, there is still no universally acceptable, safe, and effective vaccine against the disease. This strongly suggests that we still do not completely understand the factors that control and/or regulate the development and sustenance of anti-Leishmania immunity, particularly those associated with secondary (memory) immunity. Such an understanding is critically important for designing safe, effective, and universally acceptable vaccine against the disease. Here we review the literature on the correlate of protective anti-Leishmania immunity and vaccination strategies against leishmaniasis with a bias emphasis on experimental cutaneous leishmaniasis.

KEYWORDS:

adaptive immunity; cutaneous leishmaniasis; infection-induced resistance; innate immunity; vaccination; vaccine

PMID:
22661975
[PubMed]
PMCID:
PMC3361738
Free PMC Article

Images from this publication.See all images (1)Free text

Figure 1
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Frontiers Media SA Icon for PubMed Central
    Loading ...
    Write to the Help Desk